Ubiquitin ligases in cancer: functions and clinical potentials.

Ubiquitylation, a highly regulated post-translational modification, controls many cellular pathways that are critical to cell homeostasis. Ubiquitin ligases recruit substrates and promote ubiquitin transfer onto targets, inducing proteasomal degradation or non-degradative signaling. Accumulating evidence highlights the critical role of dysregulated ubiquitin ligases in processes associated with the initiation and progression of cancer. Depending on the substrate specificity and biological context, a ubiquitin ligase can act either as a tumor promoter or as a tumor suppressor. In this review, we focus on the regulatory roles of ubiquitin ligases and how perturbations of their functions contribute to cancer pathogenesis. We also briefly discuss current strategies for targeting or exploiting ubiquitin ligases for cancer therapy.

• Publication year

  2021

• Venue

  Cell Chemical Biology

• Publication date

  2021-04-27

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.chembiol.2021.04.008PMID 33974914PMCID PMC8286310
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• CRL4AMBRA1 is a master regulator of D-type cyclins

  2021cited by this paper
• Systematic characterization of mutations altering protein degradation in human cancers.

  2021cited by this paper
• The AMBRA1 E3 ligase adaptor regulates the stability of cyclin D

  2021cited by this paper
• The Pleiotropic Role of the KEAP1/NRF2 Pathway in Cancer

  2020cited by this paper
• Small molecule-induced polymerization triggers degradation of BCL6

  2020cited by this paper
• Epigenetic silencing of the ubiquitin ligase subunit FBXL7 impairs c-SRC degradation and promotes epithelial-to-mesenchymal transition and metastasis

  2020cited by this paper
• Discovery of a molecular glue promoting CDK12-DDB1 interaction to trigger cyclin K degradation

  2020cited by this paper
• Complex Cartography: Regulation of E2F Transcription Factors by Cyclin F and Ubiquitin.

  2020cited by this paper
• SPOP and cancer: a systematic review.

  2020cited by this paper
• The CDK inhibitor CR8 acts as a molecular glue degrader that depletes cyclin K

  2020cited by this paper
• Rational discovery of molecular glue degraders via scalable chemical profiling

  2020cited by this paper
• ERK signalling: a master regulator of cell behaviour, life and fate

  2020cited by this paper
• Dioscin: A new potential inhibitor of Skp2 for cancer therapy

  2020cited by this paper
• Author Correction: mTOR at the nexus of nutrition, growth, ageing and disease

  2020cited by this paper
• RIT1 oncoproteins escape LZTR1-mediated proteolysis

  2019cited by this paper
• Nrf2 Activation Promotes Lung Cancer Metastasis by Inhibiting the Degradation of Bach1.

  2019cited by this paper
• Structural complementarity facilitates E7820-mediated degradation of RBM39 by DCAF15

  2019cited by this paper
• E2F1 proteolysis via SCF‐cyclin F underlies synthetic lethality between cyclin F loss and Chk1 inhibition

  2019cited by this paper
• LZTR1 facilitates polyubiquitination and degradation of RAS-GTPases

  2019cited by this paper
• Ubiquitin Ligases in Cancer Immunotherapy - Balancing Antitumor and Autoimmunity.

  2019cited by this paper
• Structural Basis and Kinetic Pathway of RBM39 Recruitment to DCAF15 by a Sulfonamide Molecular Glue E7820.

  2019cited by this paper
• Development of targeted protein degradation therapeutics

  2019cited by this paper
• Structural basis of indisulam-mediated RBM39 recruitment to DCAF15 E3 ligase complex

  2019cited by this paper
• The PI3K–AKT network at the interface of oncogenic signalling and cancer metabolism

  2019cited by this paper
• Cyclin F Controls Cell-Cycle Transcriptional Outputs by Directing the Degradation of the Three Activator E2Fs.

  2019cited by this paper
• First targeted protein degrader hits the clinic

  2019cited by this paper
• Therapeutic targeting of the E3 ubiquitin ligase SKP2 in T-ALL

  2019cited by this paper
• Mutations in LZTR1 drive human disease by dysregulating RAS ubiquitination

  2018cited by this paper
• Dominant Noonan syndrome-causing LZTR1 mutations specifically affect the Kelch domain substrate-recognition surface and enhance RAS-MAPK signaling

  2018cited by this paper
• Loss of KLHL6 promotes diffuse large B-cell lymphoma growth and survival by stabilizing the mRNA decay factor Roquin2

  2018cited by this paper
• Tumor Immunology

  2018cited by this paper
• LZTR1 is a regulator of RAS ubiquitination and signaling

  2018cited by this paper
• Cereblon modulator iberdomide induces degradation of the transcription factors Ikaros and Aiolos: immunomodulation in healthy volunteers and relevance to systemic lupus erythematosus

  2018cited by this paper
• BCL-2 family proteins: changing partners in the dance towards death.

  2018cited by this paper
• FBXO38 mediates PD-1 ubiquitination and regulates anti-tumour immunity of T cells

  2018cited by this paper
• Genome-wide CRISPR Screens in Primary Human T Cells Reveal Key Regulators of Immune Function

  2018cited by this paper
• Synthetic lethal therapies for cancer: what’s next after PARP inhibitors?

  2018cited by this paper
• The long tail of oncogenic drivers in prostate cancer

  2018cited by this paper
• Ubiquitin System

  2018cited by this paper
• Keap1 loss promotes Kras-driven lung cancer and results in a dependence on glutaminolysis

  2017cited by this paper
• BCL-2 family proteins: changing partners in the dance towards death

  2017cited by this paper
• Systemic Therapy for Metastatic Renal-Cell Carcinoma.

  2017cited by this paper
• Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers

  2017cited by this paper
• MDM2/X inhibitors under clinical evaluation: perspectives for the management of hematological malignancies and pediatric cancer

  2017cited by this paper
• The VHL Tumor Suppressor Gene: Insights into Oxygen Sensing and Cancer.

  2017cited by this paper
• Targeted Protein Degradation: from Chemical Biology to Drug Discovery.

  2017cited by this paper
• Chemically Induced Degradation of the Oncogenic Transcription Factor BCL6.

  2017cited by this paper
• Phase I Dose-Escalation Trial of PT2385, a First-in-Class Hypoxia-Inducible Factor-2α Antagonist in Patients With Previously Treated Advanced Clear Cell Renal Cell Carcinoma.

  2017cited by this paper
• Anticancer sulfonamides target splicing by inducing RBM39 degradation via recruitment to DCAF15

  2017cited by this paper
• PTEN counteracts FBXL2 to promote IP3R3– and Ca2+–mediated apoptosis limiting tumour growth

  2017cited by this paper
• Emerging Biological Principles of Metastasis.

  2017cited by this paper
• Selective degradation of splicing factor CAPERα by anticancer sulfonamides.

  2017cited by this paper
• Ubiquitin ligases in oncogenic transformation and cancer therapy

  2017cited by this paper
• Cyclin D-CDK4 kinase destabilizes PD-L1 via Cul3SPOP to control cancer immune surveillance

  2017cited by this paper
• AKT/PKB Signaling: Navigating the Network.

  2017cited by this paper
• Targeting the MDM2-p53 Protein-Protein Interaction for New Cancer Therapy: Progress and Challenges.

  2017cited by this paper
• Opposing effects of cancer type-specific SPOP mutations on BET protein degradation and sensitivity to BET inhibitors

  2017cited by this paper
• Cell cycle proteins as promising targets in cancer therapy

  2017cited by this paper
• Induced protein degradation: an emerging drug discovery paradigm

  2016cited by this paper
• Cbl-b deficiency renders T cells resistant to PD-L1/PD-1 mediated suppression

  2016cited by this paper
• Building a Regulatory Network with Short Linear Sequence Motifs: Lessons from the Degrons of the Anaphase-Promoting Complex.

  2016cited by this paper
• The Emerging Hallmarks of Cancer Metabolism.

  2016cited by this paper
• Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway.

  2016cited by this paper
• Cyclin D1, cancer progression, and opportunities in cancer treatment

  2016cited by this paper
• Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas

  2016cited by this paper
• Structural insights into the catalysis and regulation of E3 ubiquitin ligases

  2016cited by this paper
• A novel cereblon modulator recruits GSPT1 to the CRL4CRBN ubiquitin ligase

  2016cited by this paper
• SPOP Promotes Ubiquitination and Degradation of the ERG Oncoprotein to Suppress Prostate Cancer Progression.

  2015cited by this paper
• Dysregulation of ubiquitin ligases in cancer.

  2015cited by this paper
• Combination cancer immunotherapy and new immunomodulatory targets

  2015cited by this paper
• Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS

  2015cited by this paper
• Histone H1 couples initiation and amplification of ubiquitin signalling after DNA damage

  2015cited by this paper
• Signal transduction in cancer.

  2015cited by this paper
• Truncated ERG Oncoproteins from TMPRSS2-ERG Fusions Are Resistant to SPOP-Mediated Proteasome Degradation.

  2015cited by this paper
• Roles of F-box proteins in cancer

  2014cited by this paper
• In vivo discovery of immunotherapy targets in the tumour microenvironment

  2014cited by this paper
• The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins

  2014cited by this paper
• The ubiquitin proteasome system - implications for cell cycle control and the targeted treatment of cancer.

  2014cited by this paper
• SCF ubiquitin ligase-targeted therapies

  2014cited by this paper
• Inhibition of Cullin-RING E3 ubiquitin ligase 7 by simian virus 40 large T antigen

  2014cited by this paper
• EGF receptor trafficking: consequences for signaling and cancer

  2014cited by this paper
• Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells

  2014cited by this paper
• Disruption of the PRKCD–FBXO25–HAX-1 axis attenuates the apoptotic response and drives lymphomagenesis

  2014cited by this paper
• FBXL2- and PTPL1-mediated degradation of p110-free p85β regulatory subunit controls the PI(3)K signalling cascade

  2013cited by this paper
• Signaling pathways that control cell proliferation.

  2013cited by this paper
• Building and remodelling Cullin–RING E3 ubiquitin ligases

  2013cited by this paper
• MDM2, MDMX and p53 in oncogenesis and cancer therapy

  2013cited by this paper
• The RASopathies.

  2013cited by this paper
• Inhibitors of SCF-Skp2/Cks1 E3 ligase block estrogen-induced growth stimulation and degradation of nuclear p27kip1: therapeutic potential for endometrial cancer.

  2013cited by this paper
• Regulation of DNA damage responses by ubiquitin and SUMO.

  2013cited by this paper
• The emerging role of the Nrf2–Keap1 signaling pathway in cancer

  2013cited by this paper
• A cyclin without cyclin-dependent kinases: cyclin F controls genome stability through ubiquitin-mediated proteolysis.

  2013cited by this paper
• Mechanisms and function of substrate recruitment by F-box proteins

  2013cited by this paper
• Pharmacological inactivation of Skp2 SCF ubiquitin ligase restricts cancer stem cell traits and cancer progression.

  2013cited by this paper
• Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4CRBN

  2013cited by this paper
• HECT and RING finger families of E3 ubiquitin ligases at a glance

  2012cited by this paper
• Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer

  2012cited by this paper
• FBXO11 targets BCL6 for degradation and is inactivated in diffuse large B-cell lymphomas

  2012cited by this paper
• Fbxw7α- and GSK3-mediated degradation of p100 is a pro-survival mechanism in multiple myeloma

  2012cited by this paper
• Passing the baton: the HIF switch.

  2012cited by this paper

• SCF-FBXO31 E3 ubiquitin ligase in cancer: Molecular insights and clinical implications.

  2026cites this paper
• Editorial: Ubiquitination in tumor pathogenesis and progression and its therapeutic potential

  2026cites this paper
• Interaction of CSN4 to DDB1 regulates its stability and function in DNA damage signaling

  2026cites this paper
• Mebendazole inhibits PELI3-mediated ubiquitination of TRADD in non-small cell lung cancer cells

  2026cites this paper
• Proteome-wide C-degron activity profiling connects conditional regulation of the CTLH E3 ligase complex to ribosome biogenesis

  2026cites this paper
• Elevated FBXO45 promotes TFG ubiquitination and drives lung metastasis of hepatocellular carcinoma

  2025cites this paper
• Characterization of E1 enzyme dependencies in mutant-UBA1 human cells reveals UBA6 as a novel therapeutic target in VEXAS syndrome

  2025cites this paper
• Integrated mendelian randomization and bioinformatics approach unveiling the immunological and prognostic significance of FBXO2 in breast cancer

  2025cites this paper
• Neddylation inhibition induces DNA double-strand breaks, hampering tumor growth in vivo, and promotes radiosensitivity in PAX3–FOXO1 rhabdomyosarcoma

  2025cites this paper
• UBE3A Inhibits Trophoblast Cell Migration and Invasion by Promoting ITGB1 Degradation and Affecting PI3K/AKT Signaling.

  2025cites this paper
• VRK2 targeting potentiates anti-PD-1 immunotherapy in hepatocellular carcinoma through MYC destabilization

  2025cites this paper
• Molecular reactivity in maternal pregnancy blood and neonatal dried blood spots is associated with risk of pediatric acute lymphoblastic leukemia.

  2025cites this paper
• Cul5Wsb2 uses BCL2 proteins as co-receptors to target Bim for degradation

  2025cites this paper
• The RING finger E3 ligase RNF25 protects DNA replication forks independently of its canonical roles in ubiquitin signaling

  2025cites this paper
• Tuning ubiquitin transfer by RING E3 ubiquitin ligases through the linchpin residue

  2025cites this paper
• Ubiquitination Enzymes in Cancer, Cancer Immune Evasion, and Potential Therapeutic Opportunities

  2025cites this paper
• The RING Finger E3 Ligase RNF25 Protects DNA Replication Forks Independently of its Canonical Roles in Ubiquitin Signaling

  2025cites this paper
• The FBXO45–GEF-H1 Axis Controls Germinal Center Formation and B-cell Lymphomagenesis

  2025cites this paper
• A Perspective on Therapeutic Targeting Against Ubiquitin Ligases to Stabilize Tumor Suppressor Proteins

  2025cites this paper
• YTHDF1/RNF7/p27 axis promotes prostate cancer progression

  2025cites this paper
• Exploring the molecular mechanism of Xiao Ji (Cirsium setosum) in treating bladder cancer using network pharmacology and molecular docking

  2025cites this paper
• FBXO22 deficiency defines a pleiotropic syndrome of growth restriction and multi-system anomalies associated with a unique epigenetic signature

  2024cites this paper
• USP7 deubiquitinates KRAS and promotes non-small cell lung cancer.

  2024cites this paper
• The treatment interventions and targets of cancer cachexia research during the past decade: a systematic review of the literature

  2024cites this paper
• TRIM22 induces cellular senescence by targeting PHLPP2 in hepatocellular carcinoma

  2024cites this paper
• DCAF15 control of cohesin dynamics sustains acute myeloid leukemia

  2024cites this paper
• The emerging and diverse roles of F-box proteins in spermatogenesis and male infertility

  2024cites this paper
• SCFFBXW11 Complex Targets Interleukin-17 Receptor A for Ubiquitin–Proteasome-Mediated Degradation

  2024cites this paper
• Ubiquitin E3 ligases assisted technologies in protein degradation: Sharing Pathways in Neurodegenerative Disorders and Cancer.

  2024cites this paper
• MYOD-SKP2 axis boosts tumorigenesis in fusion negative rhabdomyosarcoma by preventing differentiation through p57Kip2 targeting

  2023cites this paper
• Emerging roles of the HECT E3 ubiquitin ligases in gastric cancer

  2023cites this paper
• Cell cycle exits and U-turns: Quiescence as multiple reversible forms of arrest

  2023cites this paper
• Open resources for chemical probes and their implications for future drug discovery

  2023cites this paper
• Modulation of the ubiquitin‐proteasome system by phytochemicals: Therapeutic implications in malignancies with an emphasis on brain tumors

  2023cites this paper
• SCFFBXW11 complex targets interleukin-17 receptor A for ubiquitin-proteasome-mediated degradation

  2023cites this paper
• Elevated FBXW10 drives hepatocellular carcinoma tumorigenesis via AR-VRK2 phosphorylation-dependent GAPDH ubiquitination in male transgenic mice.

  2023cites this paper
• Panapophenanthrin, a Rare Oligocyclic Diterpene from Panus strigellus

  2023cites this paper
• Targeting reversible post-translational modifications with PROTACs: a focus on enzymes modifying protein lysine and arginine residues

  2023cites this paper
• Target protein degradation by protacs: A budding cancer treatment strategy.

  2023cites this paper
• Knockout of c-Cbl/Cbl-b slows c-Met trafficking resulting in enhanced signaling in corneal epithelial cells

  2023cites this paper
• The CRL3gigaxonin ubiquitin ligase–USP15 pathway governs the destruction of neurofilament proteins

  2023cites this paper
• Mechanisms underlying linear ubiquitination and implications in tumorigenesis and drug discovery

  2023cites this paper
• E3 ubiquitin ligases in lung cancer: Emerging insights and therapeutic opportunities.

  2023cites this paper
• Extracellular targeted protein degradation: an emerging modality for drug discovery

  2023cites this paper
• Catalytic Protein Inhibitors.

  2023cites this paper
• Defective protein degradation in genetic disorders.

  2022cites this paper
• The intricate interplay between HIFs, ROS, and the ubiquitin system in the tumor hypoxic microenvironment.

  2022cites this paper
• Receptor Elimination by E3 Ubiquitin Ligase Recruitment (REULR): A Targeted Protein Degradation Toolbox

  2022influential citation
• FBXL4 suppresses mitophagy by restricting the accumulation of NIX and BNIP3 mitophagy receptors

  2022cites this paper
• Identification of orphan ligand-receptor relationships using a cell-based CRISPRa enrichment screening platform

  2022cites this paper
• Targeting the untargetable: RB1-deficient tumours are vulnerable to Skp2 ubiquitin ligase inhibition

  2022cites this paper
• USP13 modulates the stability of the APC/C adaptor CDH1

  2022cites this paper
• New classes of E3 ligases illuminated by chemical probes.

  2022cites this paper
• Chemical biology tools to study Deubiquitinases and Ubl proteases.

  2022cites this paper
• Almost famous: Human adenoviruses (and what they have taught us about cancer)

  2021cites this paper
• dbPTM in 2022: an updated database for exploring regulatory networks and functional associations of protein post-translational modifications

  2021cites this paper
• Tools for Decoding Ubiquitin Signaling in DNA Repair

  2021cites this paper
• Potential of E3 Ubiquitin Ligases in Cancer Immunity: Opportunities and Challenges

  2021cites this paper
• From the Evasion of Degradation to Ubiquitin-Dependent Protein Stabilization

  2021cites this paper
• F-box proteins in cancer stemness: an emerging prognostic and therapeutic target.

  2021cites this paper